{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:36:28Z","timestamp":1794490588236,"version":"4.9.1"},"reference-count":97,"publisher":"Elsevier BV","issue":"50","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["NIH AI 155346"],"award-info":[{"award-number":["NIH AI 155346"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.vaccine.2021.09.040","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T18:58:01Z","timestamp":1632769081000},"page":"7321-7331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Recombinant BCGs for tuberculosis and bladder cancer"],"prefix":"10.1016","volume":"39","author":[{"given":"Alok K.","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geetha","family":"Srikrishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trinity J.","family":"Bivalacqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8734-4118","authenticated-orcid":false,"given":"William R.","family":"Bishai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.09.040_b0005","first-page":"48","article-title":"The history of BCG: early history. BCG Vaccination Against Tuberculosis, London","author":"Gu\u00e9rin","year":"1957","journal-title":"J&H Churchill"},{"key":"10.1016\/j.vaccine.2021.09.040_b0010","first-page":"1485","article-title":"Preventive Vaccination Against Tuberculosis with BCG","volume":"24","author":"Calmette","year":"1931","journal-title":"Proc R Soc Med"},{"key":"10.1016\/j.vaccine.2021.09.040_b0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001012","article-title":"The BCG World Atlas: a database of global BCG vaccination policies and practices","volume":"8","author":"Zwerling","year":"2011","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2021.09.040_b0020","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g4643","article-title":"Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis","volume":"349","author":"Roy","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2021.09.040_b0025","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(06)68507-3","article-title":"Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness","volume":"367","author":"Trunz","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2021.09.040_b0030","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/cid\/cit790","article-title":"Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials","volume":"58","author":"Mangtani","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2021.09.040_b0035","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.3389\/fimmu.2017.01134","article-title":"What Have We Learnt about BCG Vaccination in the Last 20 Years?","volume":"8","author":"Dockrell","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2021.09.040_b0040","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nrmicro1211","article-title":"The success and failure of BCG - implications for a novel tuberculosis vaccine","volume":"3","author":"Andersen","year":"2005","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2021.09.040_b0045","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.3389\/fimmu.2019.02965","article-title":"The Intriguing History of Cancer Immunotherapy","volume":"10","author":"Dobosz","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2021.09.040_b0050","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"10.1016\/j.vaccine.2021.09.040_b0055","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1464-410X.2012.11754.x","article-title":"Bacillus Calmette-Gu\u00e9rin immunotherapy for genitourinary cancer","volume":"112","author":"Gandhi","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.vaccine.2021.09.040_b0060","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41585-018-0055-4","article-title":"Mechanisms of BCG immunotherapy and its outlook for bladder cancer","volume":"15","author":"Pettenati","year":"2018","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.vaccine.2021.09.040_b0065","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.cell.2020.08.051","article-title":"Activate: Randomized Clinical Trial of BCG Vaccination against Infection in the Elderly","volume":"183","author":"Giamarellos-Bourboulis","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2021.09.040_b0070","article-title":"ACTIVATE-2: A double-blind randomized trial of BCG vaccination against COVID-19 in individuals at risk","author":"Tsilika","year":"2021","journal-title":"MedRxiv"},{"key":"10.1016\/j.vaccine.2021.09.040_b0075","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.2217\/fmb-2018-0026","article-title":"Heterologous effects of infant BCG vaccination: potential mechanisms of immunity","volume":"13","author":"Butkeviciute","year":"2018","journal-title":"Future Microbiology"},{"key":"10.1016\/j.vaccine.2021.09.040_b0080","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41577-020-0285-6","article-title":"Defining trained immunity and its role in health and disease","volume":"20","author":"Netea","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2021.09.040_b0085","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/trstmh\/tru168","article-title":"Trained immunity: consequences for the heterologous effects of BCG vaccination","volume":"109","author":"Kleinnijenhuis","year":"2015","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2021.09.040_b0090","doi-asserted-by":"crossref","unstructured":"Netea MG, Joosten LAB, Latz E, Mills KHG, Natoli G, Stunnenberg HG, et al. Trained immunity: A program of innate immune memory in health and disease. Science 2016;352:aaf1098. 10.1126\/science.aaf1098.","DOI":"10.1126\/science.aaf1098"},{"key":"10.1016\/j.vaccine.2021.09.040_b0095","doi-asserted-by":"crossref","first-page":"17537","DOI":"10.1073\/pnas.1202870109","article-title":"Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes","volume":"109","author":"Kleinnijenhuis","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2021.09.040_b0100","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1016\/j.celrep.2016.11.011","article-title":"Immunometabolic Pathways in BCG-Induced Trained Immunity","volume":"17","author":"Arts","year":"2016","journal-title":"Cell Reports"},{"key":"10.1016\/j.vaccine.2021.09.040_b0105","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.cell.2017.12.031","article-title":"BCG Educates Hematopoietic Stem Cells to Generate Protective Innate Immunity against Tuberculosis","volume":"172","author":"Kaufmann","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2021.09.040_b0110","doi-asserted-by":"crossref","DOI":"10.1172\/JCI148291","article-title":"BCG turns 100: its nontraditional uses against viruses, cancer, and immunologic diseases","volume":"131","author":"Singh","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2021.09.040_b0115","unstructured":"Global tuberculosis report 2020. Geneva: World Health Organization; 2020."},{"key":"10.1016\/j.vaccine.2021.09.040_b0120","unstructured":"WHO: Global TB progress at risk. World Health Organization, Geneva 2020."},{"key":"10.1016\/j.vaccine.2021.09.040_b0125","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1098\/rstb.2011.0097","article-title":"Tuberculosis vaccines: beyond bacille Calmette-Gu\u00e9rin","volume":"366","author":"McShane","year":"2011","journal-title":"Phil Trans R Soc B"},{"key":"10.1016\/j.vaccine.2021.09.040_b0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002607","article-title":"Vaccines against Tuberculosis: Where Are We and Where Do We Need to Go?","volume":"8","author":"Ottenhoff","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2021.09.040_b0135","unstructured":"BCG vaccines: WHO position paper \u2013 February 2018. Wkly Epidemiol Rec 2018;93:73\u201396."},{"key":"10.1016\/j.vaccine.2021.09.040_b0140","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1714021","article-title":"Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination","volume":"379","author":"Nemes","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.09.040_b0145","doi-asserted-by":"crossref","unstructured":"Zimmermann P, Curtis N. Factors That Influence the Immune Response to Vaccination. Clin Microbiol Rev 2019;32. 10.1128\/CMR.00084-18.","DOI":"10.1128\/CMR.00084-18"},{"key":"10.1016\/j.vaccine.2021.09.040_b0150","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.vaccine.2019.10.072","article-title":"Preferred product characteristics for therapeutic vaccines to improve tuberculosis treatment outcomes: Key considerations from World Health Organization consultations","volume":"38","author":"Vekemans","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.09.040_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2020.101431","article-title":"Key recent advances in TB vaccine development and understanding of protective immune responses against Mycobacterium tuberculosis","volume":"50","author":"Scriba","year":"2020","journal-title":"Semin Immunol"},{"key":"10.1016\/j.vaccine.2021.09.040_b0160","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(13)60177-4","article-title":"Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial","volume":"381","author":"Tameris","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2021.09.040_b0165","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijid.2017.01.030","article-title":"Experimental animal modelling for TB vaccine development","volume":"56","author":"Cardona","year":"2017","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.09.040_b0170","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1128\/CVI.00394-14","article-title":"Intranasal administration of Mycobacterium bovis BCG induces superior protection against aerosol infection with Mycobacterium tuberculosis in mice","volume":"21","author":"Derrick","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2021.09.040_b0175","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41586-019-1817-8","article-title":"Prevention of tuberculosis in macaques after intravenous BCG immunization","volume":"577","author":"Darrah","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2021.09.040_b0180","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41591-019-0347-0","article-title":"Protection against tuberculosis by mucosal BCG administration","volume":"25","author":"Scriba","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2021.09.040_b0185","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41591-018-0319-9","article-title":"Prevention of tuberculosis infection and disease by local BCG in repeatedly exposed rhesus macaques","volume":"25","author":"Dijkman","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2021.09.040_b0190","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.tube.2016.09.004","article-title":"Alternative BCG delivery strategies improve protection against Mycobacterium tuberculosis in non-human primates: Protection associated with mycobacterial antigen-specific CD4 effector memory T-cell populations","volume":"101","author":"Sharpe","year":"2016","journal-title":"Tuberculosis (Edinb)"},{"issue":"Suppl","key":"10.1016\/j.vaccine.2021.09.040_b0195","first-page":"1","article-title":"Tuberculosis prevention Trial","volume":"72","author":"Baily","year":"1980","journal-title":"Madras. Indian J Med Res"},{"key":"10.1016\/j.vaccine.2021.09.040_b0200","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1016\/j.vaccine.2020.08.016","article-title":"The safety of BCG revaccination: A systematic review","volume":"39","author":"Bannister","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.09.040_b0205","article-title":"Recombinant BCG overexpressing a STING agonist elicits trained immunity and improved antitumor efficacy in non-muscle invasive bladder cancer","author":"Singh","year":"2020","journal-title":"BioRxiv"},{"key":"10.1016\/j.vaccine.2021.09.040_b0210","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0167-7799(97)01134-7","article-title":"The genetic reconstruction of BCG as a new immunotherapeutic tool","volume":"15","author":"O\u2019Donnell","year":"1997","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.vaccine.2021.09.040_b0215","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nrmicro.2016.131","article-title":"ESX secretion systems: mycobacterial evolution to counter host immunity","volume":"14","author":"Gr\u00f6schel","year":"2016","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2021.09.040_b0220","doi-asserted-by":"crossref","first-page":"17078","DOI":"10.1038\/srep17078","article-title":"Impact of Mycobacterium tuberculosis RD1-locus on human primary dendritic cell immune functions","volume":"5","author":"Etna","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2021.09.040_b0225","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3389\/fimmu.2018.00121","article-title":"Next-Generation Vaccines Based on Bacille Calmette-Gu\u00e9rin","volume":"9","author":"Nieuwenhuizen","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2021.09.040_b0230","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/351456a0","article-title":"New use of BCG for recombinant vaccines","volume":"351","author":"Stover","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2021.09.040_b0235","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1586\/erv.12.94","article-title":"Prime-boost approaches to tuberculosis vaccine development","volume":"11","author":"Dalmia","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2021.09.040_b0240","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1586\/ers.10.25","article-title":"Boosting BCG to protect against TB","volume":"4","author":"Rouanet","year":"2010","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.vaccine.2021.09.040_b0245","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1086\/314640","article-title":"Human T cell responses to the ESAT-6 antigen from Mycobacterium tuberculosis","volume":"179","author":"Ravn","year":"1999","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.09.040_b0250","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1172\/JCI84978","article-title":"ESAT-6-dependent cytosolic pattern recognition drives noncognate tuberculosis control in vivo","volume":"126","author":"Kupz","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2021.09.040_b0255","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/nm859","article-title":"Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis","volume":"9","author":"Pym","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2021.09.040_b0260","doi-asserted-by":"crossref","unstructured":"Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic\u2019 S. Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci U S A 2000;97:13853\u20138. 10.1073\/pnas.250480397.","DOI":"10.1073\/pnas.250480397"},{"key":"10.1016\/j.vaccine.2021.09.040_b0265","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1128\/IAI.71.4.1672-1679.2003","article-title":"A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis","volume":"71","author":"Horwitz","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2021.09.040_b0270","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.vaccine.2005.08.001","article-title":"Extraordinarily few organisms of a live recombinant BCG vaccine against tuberculosis induce maximal cell-mediated and protective immunity","volume":"24","author":"Horwitz","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.09.040_b0275","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/j.vaccine.2005.10.002","article-title":"A novel live recombinant mycobacterial vaccine against bovine tuberculosis more potent than BCG","volume":"24","author":"Horwitz","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.09.040_b0280","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1086\/592450","article-title":"A new recombinant bacille Calmette-Gu\u00e9rin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers","volume":"198","author":"Hoft","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.09.040_b0285","doi-asserted-by":"crossref","first-page":"5200","DOI":"10.1128\/IAI.00434-08","article-title":"A Replication-Limited Recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeficiency virus-positive persons is safer and more efficacious than BCG","volume":"76","author":"Tullius","year":"2008","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2021.09.040_b0290","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3389\/fcimb.2016.00003","article-title":"Evaluation of Immunogenicity and Protective Efficacy Elicited by Mycobacterium bovis BCG Overexpressing Ag85A Protein against Mycobacterium tuberculosis Aerosol Infection","volume":"6","author":"Xu","year":"2016","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.vaccine.2021.09.040_b0295","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/563838","article-title":"Immunogenicity and protective efficacy of a novel recombinant BCG strain overexpressing antigens Ag85A and Ag85B","volume":"2012","author":"Wang","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.vaccine.2021.09.040_b0300","doi-asserted-by":"crossref","first-page":"10587","DOI":"10.1007\/s00253-015-6962-x","article-title":"A live attenuated BCG vaccine overexpressing multistage antigens Ag85B and HspX provides superior protection against Mycobacterium tuberculosis infection","volume":"99","author":"Yuan","year":"2015","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.vaccine.2021.09.040_b0305","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jmii.2012.11.005","article-title":"Evaluation of protective efficacy conferred by a recombinant Mycobacterium bovis BCG expressing a fusion protein of Ag85A-ESAT-6","volume":"47","author":"Deng","year":"2014","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.vaccine.2021.09.040_b0310","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-3083.2012.02726.x","article-title":"Novel recombinant BCG coexpressing Ag85B, ESAT-6 and Rv2608 elicits significantly enhanced cellular immune and antibody responses in C57BL\/6 mice","volume":"76","author":"Lu","year":"2012","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.vaccine.2021.09.040_b0315","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.micpath.2014.03.011","article-title":"Recombinant BCG coexpressing Ag85B, ESAT-6 and Rv3620c elicits specific Th1 immune responses in C57BL\/6 mice","volume":"69\u201370","author":"Yang","year":"2014","journal-title":"Microb Pathog"},{"key":"10.1016\/j.vaccine.2021.09.040_b0320","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1574-695X.2007.00322.x","article-title":"Recombinant BCG coexpressing Ag85B, ESAT-6 and mouse-IFN-gamma confers effective protection against Mycobacterium tuberculosis in C57BL\/6 mice","volume":"51","author":"Xu","year":"2007","journal-title":"FEMS Immunol Med Microbiol"},{"key":"10.1016\/j.vaccine.2021.09.040_b0325","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1348-0421.2010.00232.x","article-title":"Novel recombinant BCG coexpressing Ag85B, ESAT-6 and mouse TNF-alpha induces significantly enhanced cellular immune and antibody responses in C57BL\/6 mice","volume":"54","author":"Shen","year":"2010","journal-title":"Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2021.09.040_b0330","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1086\/586902","article-title":"Efficacy of recombinant bacille Calmette-Gu\u00e9rin vaccine secreting interleukin-15\/antigen 85B fusion protein in providing protection against Mycobacterium tuberculosis","volume":"197","author":"Tang","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.09.040_b0335","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1016\/j.vaccine.2015.03.083","article-title":"Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system","volume":"33","author":"Bottai","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.09.040_b0340","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1016\/j.celrep.2017.02.057","article-title":"Recombinant BCG Expressing ESX-1 of Mycobacterium marinum Combines Low Virulence with Cytosolic Immune Signaling and Improved TB Protection","volume":"18","author":"Gr\u00f6schel","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.vaccine.2021.09.040_b0345","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3390\/vaccines1020120","article-title":"Nonclinical Development of BCG Replacement Vaccine Candidates","volume":"1","author":"Velmurugan","year":"2013","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2021.09.040_b0350","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.3389\/fimmu.2017.01147","article-title":"The Recombinant Bacille Calmette-Gu\u00e9rin Vaccine VPM1002: Ready for Clinical Efficacy Testing","volume":"8","author":"Nieuwenhuizen","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2021.09.040_b0355","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1586\/14760584.2014.905746","article-title":"The BCG replacement vaccine VPM1002: from drawing board to clinical trial","volume":"13","author":"Kaufmann","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2021.09.040_b0360","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00439-16","article-title":"Safety and Immunogenicity of the Recombinant Mycobacterium bovis BCG Vaccine VPM1002 in HIV-Unexposed Newborn Infants in South Africa","volume":"24","author":"Loxton","year":"2017","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2021.09.040_b0365","doi-asserted-by":"crossref","unstructured":"Gengenbacher M, Nieuwenhuizen N, Vogelzang A, Liu H, Kaiser P, Schuerer S, et al. Deletion of nuoG from the Vaccine Candidate Mycobacterium bovis BCG \u0394ureC::hly Improves Protection against Tuberculosis. MBio 2016;7. 10.1128\/mBio.00679-16.","DOI":"10.1128\/mBio.00679-16"},{"key":"10.1016\/j.vaccine.2021.09.040_b0370","doi-asserted-by":"crossref","first-page":"8740","DOI":"10.1016\/j.vaccine.2011.07.144","article-title":"Improved long-term protection against Mycobacterium tuberculosis Beijing\/W in mice after intra-dermal inoculation of recombinant BCG expressing latency associated antigens","volume":"29","author":"Reece","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.09.040_b0375","doi-asserted-by":"crossref","unstructured":"Gengenbacher M, Vogelzang A, Schuerer S, Lazar D, Kaiser P, Kaufmann SHE. Dietary pyridoxine controls efficacy of vitamin B6-auxotrophic tuberculosis vaccine bacillus Calmette-Gu\u00e9rin \u0394ureC::hly \u0394pdx1 in mice. MBio 2014;5:e01262-01214. 10.1128\/mBio.01262-14.","DOI":"10.1128\/mBio.01262-14"},{"key":"10.1016\/j.vaccine.2021.09.040_b0380","doi-asserted-by":"crossref","first-page":"4412","DOI":"10.1016\/j.vaccine.2009.05.048","article-title":"Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis","volume":"27","author":"Sun","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.09.040_b0385","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ebiom.2016.04.010","article-title":"Safety and Immunogenicity of the Recombinant BCG Vaccine AERAS-422 in Healthy BCG-na\u00efve Adults: A Randomized, Active-controlled, First-in-human Phase 1 Trial","volume":"7","author":"Hoft","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2021.09.040_b0390","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.vaccine.2015.01.058","article-title":"Deletion of zmp1 improves Mycobacterium bovis BCG-mediated protection in a guinea pig model of tuberculosis","volume":"33","author":"Sander","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.09.040_b0395","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nm.3813","article-title":"A bacterial cyclic dinucleotide activates the cytosolic surveillance pathway and mediates innate resistance to tuberculosis","volume":"21","author":"Dey","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2021.09.040_b0400","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1093\/infdis\/jiz116","article-title":"Bacillus Calmette-Gu\u00e9rin Overexpressing an Endogenous Stimulator of Interferon Genes Agonist Provides Enhanced Protection Against Pulmonary Tuberculosis","volume":"221","author":"Dey","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.09.040_b0405","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.3389\/fimmu.2019.01519","article-title":"Recombinant BCG With Bacterial Signaling Molecule Cyclic di-AMP as Endogenous Adjuvant Induces Elevated Immune Responses After Mycobacterium tuberculosis Infection","volume":"10","author":"Ning","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2021.09.040_b0410","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1146\/annurev.me.28.020177.002421","article-title":"BCG as adjuvant immunotherapy for neoplasia","volume":"28","author":"Hersh","year":"1977","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.vaccine.2021.09.040_b0415","doi-asserted-by":"crossref","first-page":"178","DOI":"10.4161\/bbug.1.3.10903","article-title":"Microbial-based therapy of cancer: current progress and future prospects","volume":"1","author":"Bernardes","year":"2010","journal-title":"Bioeng Bugs"},{"key":"10.1016\/j.vaccine.2021.09.040_b0420","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/apm.13011","article-title":"Bacillus Calmette-Gu\u00e9rin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections","volume":"128","author":"Larsen","year":"2020","journal-title":"APMIS"},{"key":"10.1016\/j.vaccine.2021.09.040_b0425","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrurol.2014.15","article-title":"The mechanism of action of BCG therapy for bladder cancer\u2013a current perspective","volume":"11","author":"Redelman-Sidi","year":"2014","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.vaccine.2021.09.040_b0430","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.3389\/fonc.2019.01270","article-title":"Immune Responses in Bladder Cancer-Role of Immune Cell Populations, Prognostic Factors and Therapeutic Implications","volume":"9","author":"Joseph","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.vaccine.2021.09.040_b0435","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1043-4666(02)00490-8","article-title":"Role of Th1 and Th2 cytokines in BCG-induced IFN-gamma production: cytokine promotion and simulation of BCG effect","volume":"21","author":"Luo","year":"2003","journal-title":"Cytokine"},{"key":"10.1016\/j.vaccine.2021.09.040_b0440","first-page":"11","article-title":"New therapies in nonmuscle invasive bladder cancer treatment. Indian","volume":"34","author":"Rayn","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.vaccine.2021.09.040_b0445","first-page":"35","article-title":"Non-muscle-invasive Bladder Cancer Management During BCG Shortages: NYU Case of the Month, February 2020","volume":"22","author":"Barlow","year":"2020","journal-title":"Rev Urol"},{"key":"10.1016\/j.vaccine.2021.09.040_b0450","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/728930","article-title":"Th1 cytokine-secreting recombinant Mycobacterium bovis bacillus Calmette-Gu\u00e9rin and prospective use in immunotherapy of bladder cancer","volume":"2011","author":"Luo","year":"2011","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.vaccine.2021.09.040_b0455","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1007\/s00253-015-6495-3","article-title":"Recombinant Mycobacterium bovis BCG for immunotherapy in nonmuscle invasive bladder cancer","volume":"99","author":"Begnini","year":"2015","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.vaccine.2021.09.040_b0460","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.intimp.2016.03.007","article-title":"Antitumor activity of recombinant Bacille Calmette-Gu\u00e9rin secreting interleukin-15-Ag85B fusion protein against bladder cancer","volume":"35","author":"Takeuchi","year":"2016","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.vaccine.2021.09.040_b0465","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3389\/fimmu.2020.00316","article-title":"Vaccination Against Tuberculosis: Revamping BCG by Molecular Genetics Guided by Immunology","volume":"11","author":"Kaufmann","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2021.09.040_b0470","doi-asserted-by":"crossref","first-page":"1748981","DOI":"10.1080\/2162402X.2020.1748981","volume":"9","author":"Rentsch","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.vaccine.2021.09.040_b0475","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/med.21649","article-title":"Agonists and inhibitors of the STING pathway: Potential agents for immunotherapy","volume":"40","author":"Wu","year":"2020","journal-title":"Med Res Rev"},{"key":"10.1016\/j.vaccine.2021.09.040_b0480","doi-asserted-by":"crossref","unstructured":"Medrano RFV, Hunger A, Mendon\u00e7a SA, Barbuto JAM, Strauss BE. Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy. Oncotarget 2017;8:71249\u201384. 10.18632\/oncotarget.19531.","DOI":"10.18632\/oncotarget.19531"},{"key":"10.1016\/j.vaccine.2021.09.040_b0485","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.molcel.2014.03.040","article-title":"The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling","volume":"54","author":"Cai","year":"2014","journal-title":"Mol Cell"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21012317?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21012317?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:07:44Z","timestamp":1759403264000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21012317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":97,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0264410X21012317"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.09.040","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recombinant BCGs for tuberculosis and bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.09.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}